Coordination among global regulators, pharmaceutical firms and investors must be strengthened to accelerate development of vaccines to prevent another potential pandemic like Covid-19 ravaging the world, the CEO of Chinese vaccine developer Sinovac Biotech said.
It is important for all stakeholders to closely interact with each other right at the start of an outbreak, Yin Weidong, who is also the chairman and president, told the China Health Investment Conference last week.
“In the race against an unknown infectious disease, humans have lessons to draw from the Covid-19 [pandemic], which was to rev up technology development to find a cure as soon as possible,” he said.
Do you have questions about the biggest topics and trends from around the world? Get the answers with SCMP Knowledge, our new platform of curated content with explainers, FAQs, analyses and infographics brought to you by our award-winning team.
Beijing-based Sinovac was among the first three Chinese pharmaceutical companies whose vaccines were approved by mainland regulators to offer protection against Covid-19, the respiratory disease caused by the coronavirus that originated in Wuhan, central China’s Hubei province in December 2019. Since being declared a global pandemic by the World Health Organization in March last year, the virus has infected more than 127 million people worldwide and claimed nearly 2.8 million lives.
Sinovac’s CoronaVac was developed using traditional technology. The inactivated virus vaccine showed an efficacy rate of 83.5 per cent in a phase three trial in Turkey, while in Brazil the rate was just above 50 per cent.
Yin said the phase three trials in Brazil focused on health care workers who were at high risk of infection. They were offered two shots of the vaccine with a two-week interval in between, which he said was the riskiest choice for vaccine evaluation because the protection rate could be at its lowest.
He said the trial showed that the vaccine offered 100 per cent protection against death, severe illness and hospital admission, and the protection rate was around 80 per cent against milder cases requiring medical treatment.
“Early investment in development and manufacturing of a new vaccine is the best tool to hedge against the uncertainty of a severe disease outbreak,” Yin said, adding that China’s overall industrial strength enabled Sinovac to ramp up production of CoronaVac vaccines.
He said the company was on track to produce 2 billion doses by June. Sinovac is one of the suppliers to Hong Kong, where nearly 440,000 people or nearly 6 per cent of the population has received at least one dose of the vaccine from one of two suppliers that includes Pfizer-BioNTech.
Yin said that the pandemic pushed pharmaceutical companies to develop vaccines using mRNA technology that had never been used before.
“The US and European countries showed higher risk tolerance level than normal in developing the advanced technology,” said Yin. “I think it proved that new technologies, though carrying high risks, should be prioritised [when there’s a health crisis].”
Unlike typical vaccines which use either dead or weakened form of virus to jump-start the body’s natural defences, mRNA vaccine relies on cells to produce proteins to fight the virus.
Two mRNA vaccines, one developed by the US-German team of Pfizer-BioNTech, and the other by US firm Moderna, are being used extensively in Europe and the US.
Gao Jianchao, an official with China’s Centre for Drug Evaluation, told the conference that Beijing was determined to deepen reforms on drug approval mechanism.
“Openness, fairness and justice are the principles to be implemented while development and innovations on new medicines are encouraged,” he said.
More from South China Morning Post:
This article Chinese vaccine developer Sinovac calls for concerted global effort to deal with future pandemics first appeared on South China Morning Post